
Andrew M Hughes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6554149/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Technology clinical trials: Turning innovation into patient benefit. Digital Health, 2021, 7, 205520762110121.	1.8	2
2	Discovery and Evaluation of Protein Biomarkers as a Signature of Wellness in Late-Stage Cancer Patients in Early Phase Clinical Trials. Cancers, 2021, 13, 2443.	3.7	4
3	Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer. Nature Medicine, 2017, 23, 114-119.	30.7	260
4	Quantification of skeletal metastases in castrateâ€resistant prostate cancer predicts progressionâ€free and overall survival. BJU International, 2014, 114, E70-E73.	2.5	30
5	Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma. Melanoma Research, 2014, 24, 40-46.	1.2	67
6	Analytical Validation of BRAF Mutation Testing from Circulating Free DNA Using the Amplification Refractory Mutation Testing System. Journal of Molecular Diagnostics, 2014, 16, 343-349.	2.8	44
7	Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma. Journal of Investigative Dermatology, 2013, 133, 1582-1590.	0.7	122
8	Analysis of Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Using Epithelial Marker-Dependent and -Independent Approaches. Journal of Thoracic Oncology, 2012, 7, 306-315.	1.1	411
9	A Pilot Study Assessing the Prognostic Value of CK18 and nDNA Biomarkers in Severe Sepsis Patients. Clinical Drug Investigation, 2012, 32, 179-187.	2.2	25
10	Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2011, 29, 1556-1563.	1.6	788
11	Circulating Tumor Cells as a Window on Metastasis Biology in Lung Cancer. American Journal of Pathology, 2011, 178, 989-996.	3.8	386
12	Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Breast Cancer Research and Treatment, 2010, 120, 461-467.	2.5	191
13	Considerations for powering a clinical proteomics study: Normal variability in the human plasma proteome. Proteomics - Clinical Applications, 2009, 3, 394-407.	1.6	15
14	Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy. American Journal of Pathology, 2009, 175, 808-816.	3.8	223
15	Isolation and Extraction of Circulating Tumor DNA from Patients with Small Cell Lung Cancer. Annals of the New York Academy of Sciences, 2008, 1137, 98-107.	3.8	90
16	Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity. Molecular Cancer Therapeutics, 2008, 7, 455-463.	4.1	56
17	Multiplexed Assays for Detection of Mutations in PIK3CA. Clinical Chemistry, 2008, 54, 757-760.	3.2	72
18	Serum biomarkers of apoptosis. European Journal of Cancer, Supplement, 2007, 5, 115-127.	2.2	0

ANDREW M HUGHES

#	Article	IF	CITATIONS
19	DNA Methylation in Circulating Tumour DNA as a Biomarker for Cancer. Biomarker Insights, 2007, 2, 117727190700200.	2.5	26
20	A first-in-man phase I tolerability and pharmacokinetic study of the cyclin-dependent kinase-inhibitor AZD5438 in healthy male volunteers. Cancer Chemotherapy and Pharmacology, 2007, 60, 391-398.	2.3	23
21	A phase I pharmacodynamic study of the effects of the cyclin-dependent kinase-inhibitor AZD5438 on cell cycle markers within the buccal mucosa, plucked scalp hairs and peripheral blood mononucleocytes of healthy male volunteers. Cancer Chemotherapy and Pharmacology, 2007, 60, 479-488.	2.3	22
22	Absolute quantification of farnesylated Ras levels in complex samples using liquid chromatography fractionation combined with tryptic digestion and electrospray tandem mass spectrometry. Analytical Biochemistry, 2006, 352, 33-40.	2.4	8
23	Staged Risk Management of Candidate Drug Efficacy. Pharmaceutical Medicine, 2005, 19, 227-232.	0.4	2
24	Effect of oral linezolid on the pressor response to intravenous tyramine. British Journal of Clinical Pharmacology, 2004, 58, 470-475.	2.4	24
25	The prostaglandin E2 receptor-1 (EP-1) mediates acid-induced visceral pain hypersensitivity in humans. Gastroenterology, 2003, 124, 18-25.	1.3	128
26	Novel approaches in oncology at AstraZeneca. European Journal of Cancer, Supplement, 2003, 1, 3-8.	2.2	7
27	Assessment of the reproducibility of intradermal administration of capsaicin as a model for inducing human pain. Pain, 2002, 99, 323-331.	4.2	51